MaxCyte Introduces the GT™ Flow Transfection System
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
MaxCyte announces the introduction of its GT™ Flow Transfection System at the 4th Annual Stem Cell Summit to be held in New York, NY. The MaxCyte GT™ Flow Transfection System is a validated, scalable technology for customizing the biological activity of cells for therapeutic use.
This system, which is supported by a US FDA Master File, enables transfection of any primary cell or cell line with >90% cell viability following loading with a range of molecules or combinations thereof, at volumes up to tens of billion cells, processed in under 30 minutes.
The MaxCyte GT™ Flow Transfection System can enable consistent cGMP-compliant cell modification in a closed-system for clinical/commercial scale manufacturing. Appropriate for either cGMP facility or point-of-care use, the GT™ Flow Transfection System allows cost-effective delivery with both autologous and allogeneic cellular therapies, customized for enhanced efficacy.
"The MaxCyte GT™ Flow Transfection System addresses two of the primary challenges hindering acceleration of effective stem cell therapies. It enables design and development of stem cell products modified to allow for improved regenerative responses and permits robust, automated, cost-effective, cGMP and regulatory-compliant product manufacturing," says Dr. Madhusudan Peshwa, Executive Vice President of Cellular Therapies at MaxCyte.
"Such reduction in efficacy and delivery risk in the early-stages of product development can significantly reduce cost, accelerate development, and enhance effectiveness, while providing for novel Intellectual Property around such engineered cell therapy and stem cell products."
"The GT™ Flow Transfection System has been validated in a marketed oncology therapy and in multiple phase I/II clinical studies in oncology and regenerative medicine applications with demonstrated ability to customize and enhance biological activity of cells and ensure robust product manufacturing," stated Mr. Douglas Doerfler, Founder, CEO and President of MaxCyte.
"We are excited to make available the MaxCyte GT™ Flow Transfection System for clinical applications at translational medical centers and to stem cell investigators involved in the discovery and development of novel pathways that facilitate development of proprietary enhanced cellular therapies and novel efficacious small molecule drugs."
This system, which is supported by a US FDA Master File, enables transfection of any primary cell or cell line with >90% cell viability following loading with a range of molecules or combinations thereof, at volumes up to tens of billion cells, processed in under 30 minutes.
The MaxCyte GT™ Flow Transfection System can enable consistent cGMP-compliant cell modification in a closed-system for clinical/commercial scale manufacturing. Appropriate for either cGMP facility or point-of-care use, the GT™ Flow Transfection System allows cost-effective delivery with both autologous and allogeneic cellular therapies, customized for enhanced efficacy.
"The MaxCyte GT™ Flow Transfection System addresses two of the primary challenges hindering acceleration of effective stem cell therapies. It enables design and development of stem cell products modified to allow for improved regenerative responses and permits robust, automated, cost-effective, cGMP and regulatory-compliant product manufacturing," says Dr. Madhusudan Peshwa, Executive Vice President of Cellular Therapies at MaxCyte.
"Such reduction in efficacy and delivery risk in the early-stages of product development can significantly reduce cost, accelerate development, and enhance effectiveness, while providing for novel Intellectual Property around such engineered cell therapy and stem cell products."
"The GT™ Flow Transfection System has been validated in a marketed oncology therapy and in multiple phase I/II clinical studies in oncology and regenerative medicine applications with demonstrated ability to customize and enhance biological activity of cells and ensure robust product manufacturing," stated Mr. Douglas Doerfler, Founder, CEO and President of MaxCyte.
"We are excited to make available the MaxCyte GT™ Flow Transfection System for clinical applications at translational medical centers and to stem cell investigators involved in the discovery and development of novel pathways that facilitate development of proprietary enhanced cellular therapies and novel efficacious small molecule drugs."
